News for Nkarta, Inc. (NKTX)

SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. ( NKTX), a biopharmaceutical company developing engineered natural killer (NK) cel

On December 31, 2024, COMMODORE CAPITAL LP (Trades, Portfolio) executed a substantial reduction in its holdings of Nkarta Inc (NKTX). The firm decreased its pos

Nkarta focuses on autoimmune diseases, with $402.5M in cash. Read why NKTX stock, currently undervalued, offers multiple opportunities despite market risks.

On December 6, 2024, Citadel Advisors LLC (Trades, Portfolio) executed a noteworthy transaction by acquiring an additional 680,632 shares of Nkarta Inc (NKTX) a

Ntrust-2 open to enroll patients with systemic sclerosis, myositis and ANCA-associated vasculitis across three parallel cohorts Investigator-Sponsored Trial (I

SOUTH SAN FRANCISCO, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. ( NKTX), a biopharmaceutical company developing engineered natural killer (NK) cel

**media[463410]**

Nkarta is working on engineered NK cell therapies for autoimmune diseases and cancer. Click here to find out why I maintain a hold sentiment on NKTX stock.

Nkarta faces competition from FATE's FT522, a CAR-NK cell therapy that might be used with reduced or no conditioning chemotherapy. See why NKTX stock is a Hold.

The most oversold stocks in the health care sector present an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When ...

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. The RSI is a momentum indicator, which compares a...

With an impressive 22.55% CAGR, global cell therapy market is poised for exponential growth, fueled by cutting-edge technologies, regulatory approvals, and...

Cullinan Therapeutics has an impressive ability to generate cash with a current cash balance of $664mn and a market cap of $1.08bn. Learn more on CGEM stock here.

U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Wednesday. Shares of UBS Group AG UBS rose during Wednesday's session following st...

Shares of Serve Robotics Inc. SERV rose sharply in today's pre-market trading as the company reported better-than-expected second-quarter sales results. Serve ...

Shares of Cutera, Inc. (NASDAQ: CUTR) fell sharply during Friday’s session after the company reported worse-than-expected fourth quarter adjusted EPS results.

Shares of RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates. Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.

"Pioneering Biotech Investment: A Patient-Centric Approach" - Explore innovative ways in which biotech investments are reshaping the industry with a focus on patient well-being. Learn how this visionary approach is driving progress in healthcare and investment, all in this insightful article.

GuruFocus Article or News written by insider and the topic is about: